全文获取类型
收费全文 | 272091篇 |
免费 | 24975篇 |
国内免费 | 16968篇 |
专业分类
耳鼻咽喉 | 2400篇 |
儿科学 | 3287篇 |
妇产科学 | 4066篇 |
基础医学 | 32234篇 |
口腔科学 | 4767篇 |
临床医学 | 36651篇 |
内科学 | 43422篇 |
皮肤病学 | 3242篇 |
神经病学 | 15450篇 |
特种医学 | 9368篇 |
外国民族医学 | 143篇 |
外科学 | 27693篇 |
综合类 | 41214篇 |
现状与发展 | 57篇 |
一般理论 | 28篇 |
预防医学 | 17805篇 |
眼科学 | 7892篇 |
药学 | 27423篇 |
241篇 | |
中国医学 | 14507篇 |
肿瘤学 | 22144篇 |
出版年
2024年 | 848篇 |
2023年 | 4184篇 |
2022年 | 10713篇 |
2021年 | 13968篇 |
2020年 | 10324篇 |
2019年 | 9211篇 |
2018年 | 9855篇 |
2017年 | 8728篇 |
2016年 | 8044篇 |
2015年 | 12258篇 |
2014年 | 15247篇 |
2013年 | 13889篇 |
2012年 | 20759篇 |
2011年 | 22760篇 |
2010年 | 13798篇 |
2009年 | 11034篇 |
2008年 | 14628篇 |
2007年 | 14533篇 |
2006年 | 14231篇 |
2005年 | 14041篇 |
2004年 | 9134篇 |
2003年 | 8646篇 |
2002年 | 7143篇 |
2001年 | 5381篇 |
2000年 | 5705篇 |
1999年 | 5998篇 |
1998年 | 3800篇 |
1997年 | 3745篇 |
1996年 | 3033篇 |
1995年 | 2783篇 |
1994年 | 2283篇 |
1993年 | 1486篇 |
1992年 | 1994篇 |
1991年 | 1669篇 |
1990年 | 1369篇 |
1989年 | 1161篇 |
1988年 | 1073篇 |
1987年 | 942篇 |
1986年 | 780篇 |
1985年 | 575篇 |
1984年 | 381篇 |
1983年 | 284篇 |
1982年 | 207篇 |
1981年 | 211篇 |
1980年 | 147篇 |
1979年 | 182篇 |
1978年 | 70篇 |
1977年 | 85篇 |
1975年 | 76篇 |
1974年 | 70篇 |
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
141.
目的:探讨40岁以上高龄女性体外受精-胚胎移植(IVF-ET)的妊娠结局,旨在为高龄女性提供生育咨询以及为改善高龄女性个体化辅助生殖治疗结局提供临床依据。方法:选择我院生殖中心2015年1月—2017年12月女方年龄≥40岁且使用自身卵子行体外受精的共2 467个治疗周期资料,对各项临床数据进行回顾性分析。结果:40岁及以上行辅助生殖治疗的患者,随着女性年龄增加获卵数明显减少(40~48岁女性平均获卵数分别为2.97、 2.69、2.17、2.01、1.77、1.61、1.68、1.29和1.00,44~48岁与40~43岁依次组间比较均P<0.05),尤其是44岁以上女性胚胎发育潜能明显降低(40~48岁囊胚形成率分别为48.90%、43.72%、33.67%、34.29%、24.39%、21.14%、26.32%、16.67%和0%,44~48岁与40~43岁组间依次比较均P<0.05)。共有518个周期行新鲜胚胎移植,结果显示,随女性年龄增加,临床妊娠率(40~48岁临床妊娠率分别为26.92%、21.15%、20.79%、10.96%、18.87%、11.11%、5.88%、0%和0%,43~48岁与40~42岁组间依次比较均P<0.05)、种植率(40~48岁种植率分别为23.65%、19.51%、17.70%、8.54%、7.49%、10.81%、5.56%、0%和0%,43~48岁与40~42岁组间依次比较均P<0.05)和活产率均显著降低(40~46岁活产率分别为18.46%、10.58%、9.90%、5.48%、5.66%、2.78%和5.88%,43~46岁与40~42岁组间依次比较均P<0.05),43岁以上者结局更差。44岁以上女性自然流产率明显增高(40~45岁流产率分别为31.43%、50.00%、52.38%、50.00%、70.00%和75.00%,44~45岁与40~43岁组间依次比较均P<0.05)。46岁女性仅1例妊娠并分娩,47岁和48岁女性均无成功妊娠。与抗苗勒管激素(AMH)>1.0 ng/mL组相比,AMH≤1.0 ng/mL组妊娠率、种植率及活产率均显著下降(27.04% vs. 14.74%,22.99% vs. 13.50%,15.88% vs. 7.37%;均P<0.05),流产率明显升高(41.27% vs. 50.00%,P<0.05)。结论:≥40岁高龄女性随年龄增长生育力逐渐降低。40~43岁年龄段女性助孕仍有一定的价值,尤其是卵巢仍有一定储备者(AMH>1.0 ng/mL),但44岁以上女性原则上不再建议ART助孕,对于46岁以上卵巢功能衰竭的女性强烈建议卵子捐赠或收养。 相似文献
142.
Luis Miguel Azogil-López Juan José Pérez-Lázaro Patricia Ávila-Pecci Esther María Medrano-Sánchez María Valle Coronado-Vázquez 《Atencion primaria / Sociedad Espa?ola de Medicina de Familia y Comunitaria》2019,51(5):278-284
Aim
The purpose of this study is to find out whether telephone referral from Primary Health Care to Internal Medicine Consult manages to reduce waiting days as compared to traditional referral. This study also aims to know how acceptable is the telephone referral to general practitioners and their patients.Design
No blind randomized controlled clinical trial.Setting
Northern Huelva Health District.Participants
154 patients.Interventions
Patients referrals from intervention clinicians were sent via telephone consultation, whereas patients referrals from control clinicians were sent by traditional via.Measurements
Number of days from referral request to Internal Medicine Consult. Number of telephone and traditional referrals. Number of doctors and patients denied. Denial reasons.Results
A statistically significant difference was found between groups, with an average of 27 (21-34) days. Among General Practitioners, 8 of the first 58 total doctors after randomization and, subsequently, 6 of the 20 doctors of the test group refused to engage in the trial because they considered “excessive time and effort consuming”. 50% of patients referred by the 14 General Practitioners finally randomized to the intervention group were denied referral by telephone due to patient's complexity.Conclusions
Telephone referral significantly reduces waiting days for Internal Medicine consult. This type of referral did not mean an “excessive time and effort consuming” to General Practitioners and was not all that beneficial to complex patients 相似文献143.
144.
目的:探讨益胃汤加味对改善原发性干燥综合征(primary sj?rgren's syndrome,pSS)气阴两虚、瘀血阻络证患者疲劳症状及免疫学指标的治疗效果。方法:将116例原发性干燥综合征患者按照随机、对照、单盲法分为治疗组与对照组,每组58例。治疗组给予益胃汤加味方,每日1剂,2次/d;对照组给予硫酸羟氯喹200 mg/次,2次/d,两组均连续治疗24周。比较治疗前后两组患者中医证候疗效、中医疲劳症状积分、疲劳症状视觉模拟评分(visual analogue scale,VAS)以及类风湿因子(rheumatoid factor,RF)与血清免疫球蛋白G(immunoglobulin G,IgG)水平。结果:治疗后治疗组患者中医证候疗效优于对照组(Z=3. 712,P0. 05);治疗组中医疲劳积分与疲劳症状视觉模拟评分改善均优于对照组(P0. 05)。治疗6个月后,治疗组IgG水平较本组治疗前明显下降(P0. 05),与对照组组间比较差异无统计学意义。治疗后两组类风湿因子与本组治疗前比较均无明显下降。治疗组不良反应率1. 75%(1/57),对照组不良反应发生率为25. 49%(13/51)。结论:与硫酸羟氯喹相比,益胃汤加味方治疗pSS,可明显改善患者疲劳及总体症状,两者均可降低血清IgG,益胃汤加味方组疗效较硫酸羟氯喹更明显。两组药物对pSS患者RF水平均无明显影响。长期用药,益胃汤加味方治疗pSS较硫酸羟氯喹更为安全。 相似文献
145.
146.
Xiaoxuan Liu Ameenat L. Solebo Livia Faes Sophie Beese Tasanee Braithwaite Matthew E. Round 《Ocular immunology and inflammation》2020,28(6):898-907
ABSTRACT
Purpose
New instrument-based techniques for anterior chamber (AC) cell counting can offer automation and objectivity above clinician assessment. This review aims to identify such instruments and its correlation with clinician estimates. 相似文献147.
148.
This paper reviews the published literature on a group of developmental disorders of the retina and retinal pigment epithelium which result in focal abnormalities in one or both eyes. They are often asymptomatic, found on routine examination and are generally non-progressive. Some are associated with other systemic abnormalities.Subject terms: Retinal diseases, Eye abnormalities 相似文献
149.
María Cabrerizo Gloria Trallero María José Pena Amaia Cilla Gregoria Megias Carmen Mu?oz-Almagro Eva Del Amo Diana Roda Ana Isabel Mensalvas Antonio Moreno-Docón Juan García-Costa Nuria Rabella Manuel Ome?aca María Pilar Romero Sara Sanbonmatsu-Gámez Mercedes Pérez-Ruiz María José Santos-Mu?oz Cristina Calvo And the study group of “Enterovirus parechovirus infections in children under ?years-old Spain” PI- 《European journal of pediatrics》2015,174(11):1511-1516
150.
Se-Jin Lee Adam Lehar Yewei Liu Chi Hai Ly Quynh-Mai Pham Michael Michaud Renata Rydzik Daniel W. Youngstrom Michael M. Shen Vesa Kaartinen Emily L. Germain-Lee Thomas A. Rando 《Proceedings of the National Academy of Sciences of the United States of America》2020,117(49):30907
Myostatin (MSTN) is a transforming growth factor-β (TGF-β) family member that normally acts to limit muscle growth. The function of MSTN is partially redundant with that of another TGF-β family member, activin A. MSTN and activin A are capable of signaling through a complex of type II and type I receptors. Here, we investigated the roles of two type II receptors (ACVR2 and ACVR2B) and two type I receptors (ALK4 and ALK5) in the regulation of muscle mass by these ligands by genetically targeting these receptors either alone or in combination specifically in myofibers in mice. We show that targeting signaling in myofibers is sufficient to cause significant increases in muscle mass, showing that myofibers are the direct target for signaling by these ligands in the regulation of muscle growth. Moreover, we show that there is functional redundancy between the two type II receptors as well as between the two type I receptors and that all four type II/type I receptor combinations are utilized in vivo. Targeting signaling specifically in myofibers also led to reductions in overall body fat content and improved glucose metabolism in mice fed either regular chow or a high-fat diet, demonstrating that these metabolic effects are the result of enhanced muscling. We observed no effect, however, on either bone density or muscle regeneration in mice in which signaling was targeted in myofibers. The latter finding implies that MSTN likely signals to other cells, such as satellite cells, in addition to myofibers to regulate muscle homeostasis.Myostatin (MSTN) is a secreted signaling molecule that normally acts to limit skeletal muscle growth (for review, see ref. 1). Mice lacking MSTN exhibit dramatic increases in muscle mass throughout the body, with individual muscles growing to about twice the normal size (2). MSTN appears to play two distinct roles in regulating muscle size, one to regulate the number of muscle fibers that are formed during development and a second to regulate the growth of those fibers postnatally. The sequence of MSTN has been highly conserved through evolution, with the mature MSTN peptide being identical in species as divergent as humans and turkeys (3). The function of MSTN has also been conserved, and targeted or naturally occurring mutations in MSTN have been shown to cause increased muscling in numerous species, including cattle (3–5), sheep (6), dogs (7), rabbits (8), rats (9), swine (10), goats (11), and humans (12). Numerous pharmaceutical and biotechnology companies have developed biologic agents capable of blocking MSTN activity, and these have been tested in clinical trials for a wide range of indications, including Duchenne and facioscapulohumeral muscular dystrophy, inclusion body myositis, muscle atrophy following falls and hip fracture surgery, age-related sarcopenia, Charcot–Marie–Tooth disease, and cachexia due to chronic obstructive pulmonary disease, end-stage kidney disease, and cancer.The finding that certain inhibitors of MSTN signaling can increase muscle mass even in Mstn−/− mice revealed that the function of MSTN as a negative regulator of muscle mass is partially redundant with at least one other TGF-β family member (13, 14), and subsequent studies have identified activin A as one of these cooperating ligands (15, 16). MSTN and activin A share many key regulatory and signaling components. For example, the activities of both MSTN and activin A can be modulated extracellularly by naturally occurring inhibitory binding proteins, including follistatin (17, 18) and the follistatin-related protein, FSTL-3 or FLRG (19, 20). Moreover, MSTN and activin A also appear to share receptor components. Based on in vitro studies, MSTN is capable of binding initially to the activin type II receptors, ACVR2 and ACVR2B (also called ActRIIA and ActRIIB) (18) followed by engagement of the type I receptors, ALK4 and ALK5 (21). In previous studies, we presented genetic evidence supporting a role for both ACVR2 and ACVR2B in mediating MSTN signaling and regulating muscle mass in vivo. Specifically, we showed that mice expressing a truncated, dominant-negative form of ACVR2B in skeletal muscle (18) or carrying deletion mutations in Acvr2 and/or Acvr2b (13) have significantly increased muscle mass. One limitation of the latter study, however, was that we could not examine the consequence of complete loss of both receptors using the deletion alleles, as double homozygous mutants die early during embryogenesis (22). Moreover, the roles that the two type I receptors, ALK4 and ALK5, play in regulating MSTN and activin A signaling in muscle in vivo have not yet been documented using genetic approaches. Here, we present the results of studies in which we used floxed alleles for each of the type II and type I receptor genes in order to target these receptors alone and in combination in muscle fibers. We show that these receptors are functionally redundant and that signaling through each of these receptors contributes to the overall control of muscle mass. 相似文献